Literature DB >> 33643535

Functional transition: Inconsistently parallel to the increase in future liver remnant volume after preoperative portal vein embolization.

Yosuke Tsuruga1, Toshiya Kamiyama2, Hirofumi Kamachi2, Tatsuya Orimo2, Shingo Shimada2, Akihisa Nagatsu2, Yoh Asahi2, Yuzuru Sakamoto2, Tatsuhiko Kakisaka2, Akinobu Taketomi2.   

Abstract

BACKGROUND: Preoperative portal vein embolization (PVE) is a widely used strategy to enable major hepatectomy in patients with insufficient liver remnant. PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase of the FLR volume (FLRV) corresponds to the functional transition after PVE remains unclear. AIM: To investigate the sequential relationship between the increase in FLRV and functional transition after preoperative PVE using 3-dimensional (3D) computed tomography (CT) and 99mTc-galactosyl-human serum albumin (99mTc-GSA) single-photon emission computed tomography (SPECT) fusion images.
METHODS: Thirty-three patients who underwent major hepatectomy following PVE at the Department of Gastroenterological Surgery I, Hokkaido University Hospital between October 2013 and March 2018 were enrolled. Three-phase dynamic multidetector CT and 99mTc-GSA SPECT scintigraphy were performed at pre-PVE, and at 1 and 2 wk after PVE; 3D 99mTc-GSA SPECT CT-fused images were constructed from the Digital Imaging and Communications in Medicine data using 3D image analysis system. Functional FLRV (FFLRV) was defined as the total liver volume × (FLR volume counts/total liver volume counts) on the 3D 99mTc-GSA SPECT CT-fused images. The calculated FFLRV was compared with FLRV.
RESULTS: FFLRV increased by a significantly larger extent than FLRV at 1 and 2 wk after PVE (P < 0.01). The increase in FFLRV and FLRV was 55.1% ± 41.6% and 26.7% ± 17.8% (P < 0.001), respectively, at 1 wk after PVE, and 64.2% ± 33.3% and 36.8% ± 18.9% (P < 0.001), respectively, at 2 wk after PVE. In 3 of the 33 patients, FFLRV levels decreased below FLRV at 2 wk. One of the three patients showed rapidly progressive fatty changes in FLR. The biopsy at 4 wk after PVE showed macro- and micro-vesicular steatosis of more than 40%, which improved to 10%. Radical resection was performed at 13 wk after PVE. The patient recovered uneventfully without any symptoms of pos-toperative liver failure.
CONCLUSION: The functional transition lagged behind the increase in FLRV after PVE in some cases. Evaluating both volume and function is needed to determine the optimal timing of hepatectomy after PVE. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  99mTc-galactosyl-human serum albumin single-photon emission computed tomography; Fatty liver change; Functional transition; Future liver remnant volume; Hepatectomy; Preoperative portal vein embolization

Year:  2021        PMID: 33643535      PMCID: PMC7898185          DOI: 10.4240/wjgs.v13.i2.153

Source DB:  PubMed          Journal:  World J Gastrointest Surg


Core Tip: Preoperative portal vein embolization (PVE) induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase in FLR volume (FLRV) corresponds to the functional transition after PVE remains unclear. We investigated the sequential relationship between the increase in the FLRV and the functional transition after preoperative PVE. The functional transition lagged behind the increase in FLRV after PVE in 3 of the 33 cases. Evaluating both volume and function is needed to determine the optimal timing of hepatectomy after PVE.

INTRODUCTION

Liver resection is often the only option for long-term survival of patients with primary or secondary liver cancer. The mortality rate after major liver resection has been reported to be 2.0%-6.8%, which is mainly due to postoperative liver failure[1-3]. Small future liver remnant volume (FLRV) is a predictor of perioperative morbidity and mortality[4]. For patients with a normal liver, a remnant volume of more than 20%-40% of the total liver or standardized liver volumes has been proposed as the threshold of surgical safety[5-9]. Preoperative portal vein embolization (PVE) is widely used to enable major liver resection with insufficient liver remnant[10-13]. PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to FLR[14,15]. However, whether the increase of the FLRV corresponds to the functional transition after PVE remains unclear. 99mTc-galactosyl-human serum albumin (99mTc-GSA) was developed as a liver scintigraphy agent that binds to the asialoglycoprotein receptor on hepatocytes[16]. 99mTc-GSA scintigraphy is frequently used for evaluating the hepatic functional reserve. 99mTc-GSA single-photon emission computed tomography (SPECT) can determine the regional distribution of hepatic function[17]. However, the spatial resolution of 99mTc-GSA SPECT is low. Furthermore, it is difficult to precisely estimate the functional reserve of FLR in patients requiring complex resection. Recently, computed tomography (CT)/99mTc-GSA SPECT fusion imaging has been reported to enable the precise evaluation of hepatic function distribution owing to the high spatial resolution provided by CT[14]. We previously reported the usefulness of calculating the functional hepatic resection rate using 3-dimensional (3D) CT/99mTc-GSA SPECT fusion imaging for patients undergoing major hepatectomy by correlation with the parenchymal hepatic resection rate (PHRR)[18]. Precise measurement of the changes in both volume and function is presumed to be obtained simultaneously using 3D CT/99mTc-GSA SPECT fusion imaging. In the present study, we investigated the sequential relationship between the increase in FLRV and the functional transition after preoperative PVE using 3D CT/99mTc-GSA SPECT fusion imaging to develop a strategy for preventing fatal liver failure after major hepatectomy.

MATERIALS AND METHODS

We retrospectively analyzed the data of 33 patients who underwent major hepatectomy following PVE at the Department of Gastroenterological Surgery I, Hokkaido University Hospital between October 2013 and March 2018. This study was reviewed and approved by the Institutional Review Board of Hokkaido University Hospital for Clinical Research (approval number: 018-0263), which waived the need for written informed consent due to the retrospective design of the study. The baseline characteristics of the patients are shown in Table 1. At our institution, preoperative PVE is generally performed for patients with a PHRR of > 60%[19]. All patients underwent a three-phase dynamic multidetector CT scan and 99mTc-GSA scintigraphy at pre-PVE, and at 1 and 2 wk after PVE.
Table 1

Patient characteristics at baseline (n = 33)

Characteristics
n
Age (yr), mean (range)67.7 (40-80)
Men/women20/13
HBsAg positivity, n (%)3 (9.0)
HCV positivity, n (%)2 (6.1)
Diagnosis, n (%)
Hilar cholangiocarcinoma20 (60.6)
Hepatoma6 (18.2)
Gallbladder cancer3 (9.1)
Intrahepatic cholangiocarcinoma2 (6.1)
Metastatic tumor2 (6.1)
Child-Pugh score (5/6/7/8), n23/7/1/2
Child-Pugh classification (A/B), n30/3
ICGR15 (%), mean (range)10.1 (1.5-33.2)
Preoperative biliary drainage, n (%)17 (51.5)
Initial resection ratio (%), mean ± SD64.5 ± 5.48
Initial CT volume of FLR (mL), mean ± SD410.9 ± 79.4
Average time between PVE and operation, d (range)30.0 (15-94)
Type of hepatectomy, n (%)
Right hepatectomy + caudal lobectomy19 (57.6)
Right hepatectomy9 (27.3)
Left trisectionectomy + caudal lobectomy4 (12.1)
Left hepatectomy + caudal lobectomy1 (3.0)
Biliary reconstruction, n (%)24 (72.7)

HBsAg: Hepatitis B virus surface antigen; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; CT: Computed tomography; FLR: Future liver remnant; PVE: Portal vein embolization.

Patient characteristics at baseline (n = 33) HBsAg: Hepatitis B virus surface antigen; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; CT: Computed tomography; FLR: Future liver remnant; PVE: Portal vein embolization.

Preoperative PVE

The ipsilateral approach was routinely used, with the contralateral approach reserved for patients for whom the ipsilateral approach was judged to be unsuitable. Ethanol is used as the embolizing agent at our institution[20]. The intrahepatic portal vein was punctured under sonographic guidance. A guidewire was inserted into the portal vein through the needle, followed by the introduction of a 5.5-French sheath introducer. Balloon occlusion was performed, and contrast material was injected until the targeted portal branches were enhanced. The balloon was then deflated, and an equal amount (equivalent to the previously injected contrast material) of 0.5% lidocaine was injected. Finally, balloon occlusion was repeated, and an equal amount of ethanol (equivalent to the previously injected contrast material or 0.5% lidocaine) was injected. The balloon was deflated after 5 min, and the complete embolization of targeted vessels was determined by test portography through a manual injection of contrast medium. Subsequently, for incomplete embolization, the ethanol injections were repeated in the same way. Finally, the 5.5-French sheath was extracted by packing the puncture tract with gelatin sponge torpedoes.

Hepatectomy

An algorithm (Hokkaido University Algorithm) incorporating the indocyanine green retention at 15 min and FLRV is generally used to determine the nature of sectionectomy required, e.g., bisectionectomy[19]. The timing of the operation after PVE was generally determined by a PHRR decrease of less than 60% at least two weeks after PVE.

3D CT/99mTc-GSA SPECT fusion imaging

Three-phase dynamic CT scan was performed with a 320-row multidetector device (Aquilion ONE; Toshiba Medical Systems Co., Otawara, Japan). The obtained Digital Imaging and Communications in Medicine (DICOM) data were imported to the 3D image analysis system (Volume Analyzer SYNAPSE VINCENT; Fuji Film Medical, Tokyo, Japan)[21]. Three-dimensional images were reconstructed from the DICOM data. 99mTc-GSA scintigraphy was performed separately from CT. Dynamic scanning was initially performed using a large-field view gamma camera (E.CAM; Siemens, Tokyo, Japan) in an anterior view, equipped with a low-energy high-resolution collimator, with the patient in a supine position after a bolus intravenous injection of 185 MBq of 99mTc-GSA. Dynamic planar images were obtained for 30 min by 147 serial frames (60 × 1 s, 87 × 20 s), with a matrix size of 128 × 128. Hepatic SPECT images were acquired after the dynamic study. The DICOM data obtained from SPECT were also imported to the SYNAPSE VINCENT and subsequently fused with the 3D CT images. Functional FLRV (FFLRV) was calculated using the following formula: FFLRV (mL) = [(total liver volume counts - resection volume counts)/total liver volume counts) × total liver volume] (mL).

Calculation of FLR to spleen attenuation ratio

Hounsfield unit attenuation values of the FLR and spleen at 10 regions of interest were obtained using unenhanced CT, and the average values were calculated. The regions were selected while taking care to avoid the vessels. The ratio of liver to spleen attenuation was then calculated.

Statistical analysis

The statistical analyses were performed using EZR software, version 1.36 (Saitama Medical Center, Jichi Medical University, Saitama, Japan)[22]. The Wilcoxon signed rank test was used for comparing FFLRV and FLRV.

RESULTS

Change in FFLRV and FLRV after PVE

FFLRV increased by a significantly larger extent than FLRV at 1 and 2 wk after PVE (Figure 1A). The FFLRV and FLRV were 55.1% ± 41.6% and 26.7% ± 17.8% (P < 0.001), respectively, at 1 wk after PVE, and 64.2% ± 33.3% and 36.8% ± 18.9% (P < 0.001), respectively, at 2 wk after PVE. We also compared FLRV and FFLRV between the groups with and without preoperative biliary drainage. However, no significant differences were observed between these two groups (Table 2). The similar tendency of the sequential increase in FLRV and FFLRV after PVE was observed in these two groups (Figure 1B and C).
Figure 1

Change in the volume of the future liver remnant after portal vein embolization. A: Change in the volume of the future liver remnant (FLR) after portal vein embolization in the whole case. FLR volume (FLRV) (dashed line) and functional FLRV (solid line); B: Change in the volume of the FLR after portal vein embolization in the group with preoperative biliary drainage; C: Change in the volume of the FLR after portal vein embolization in the group without preoperative biliary drainage. aP < 0.01. W: Week.

Table 2

Comparison of the initial liver function, future liver remnant volume, and functional future liver remnant volume between the groups with and without preoperative biliary drainage


Group with preoperative biliary drainage (n = 17)
Group without preoperative biliary drainage (n = 16)
P value
ICGR15 (%), mean ± SD9.09 ± 5.011.2 ± 7.20.28
Initial resection ratio (%), mean ± SD64.6 ± 6.3664.4 ± 4.570.692
Initial FLRV (mL), mean ± SD403.8 ± 88.6418.4 ± 70.30.402
Initial FFLRV (mL), mean ± SD366.4 ± 118.7384.0 ± 92.70.601
FLRV at 1 wk (mL), mean ± SD515.7 ± 100.9515.0 ± 101.10.914
FFLRV at 1 wk (mL), mean ± SD592 ± 114.0583.0 ± 101.00.986
FLRV at 2 wk (mL), mean ± SD550.1 ± 86.6561.1 ± 114.50.958
FFLRV at 2 wk (mL), mean ± SD640.0 ± 105.8613.0 ± 96.60.382

ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.

Change in the volume of the future liver remnant after portal vein embolization. A: Change in the volume of the future liver remnant (FLR) after portal vein embolization in the whole case. FLR volume (FLRV) (dashed line) and functional FLRV (solid line); B: Change in the volume of the FLR after portal vein embolization in the group with preoperative biliary drainage; C: Change in the volume of the FLR after portal vein embolization in the group without preoperative biliary drainage. aP < 0.01. W: Week. Comparison of the initial liver function, future liver remnant volume, and functional future liver remnant volume between the groups with and without preoperative biliary drainage ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.

Change in the difference between FLRV and FFLRV

We calculated the difference by subtracting the FLRV values from FFLRV values of all patients before and after PVE (Figure 2). The results after PVE were almost entirely positive, while in 3 patients, the FFLRV became lower than the FLRV at 2 wk after PVE. FFLRV caught up with FLRV at 3 wk after PVE in 2 of these 3 patients. Subsequently, all the patients were classified into two groups: FLRV superior group included those in whom FFLRV decreased below the FLRV at 2 wk after PVE and the FFLRV superior group included the remaining patients. No significant differences were observed when the background factors were compared between these two groups (Table 3).
Figure 2

Change in the difference between the future liver remnant volume and the functional future liver remnant volume after portal vein embolization. In three patients (solid lines), the functional future liver remnant volume became lower than the future liver remnant volume at 2 wk after portal vein embolization. W: Week.

Table 3

Comparison of the background factors between the functional future liver remnant volume superior group and future liver remnant volume superior group


FFLRV superior group (n = 30)
FLRV superior group (n = 3)
Age (yr), mean ± SD67.4 ± 9.169.7 ± 9.5
Gender
Male, n (%)18 (60.0)2 (66.7)
Female, n (%)12 (40.0)1 (33.3)
Body mass index (kg/m2), mean ± SD21.8 ± 3.523.4 ± 7.0
Comorbidity (n)Diabetes (5), hypertension (3), dyslipidemia (1), COPD (1), alcoholism (1), angina (1), lacunar infarction (1)Diabetes (1), fatty liver (1), alcoholism (1)
HBV/HCV infection (n)3/10/1
Child-Pugh score, mean ± SD5.4 ± 0.95.7 ± 0.6
ICGR15 (%), mean ± SD 10.4 ± 6.37.2 ± 2.0
Initial resection ratio (%), mean ± SD64.3 ± 5.666.8 ± 4.4
Initial FLRV (mL), mean ± SD405.4 ± 79.0466.3 ± 73.2

Functional future liver remnant volume (FFLRV) superior group included the patients without FFLRV decrease below the future liver remnant volume (FLRV) at 2 wk after PVE. FLRV superior group included the patients with FFLRV decrease below the FLRV at 2 weeks after PVE. SD: Standard deviation; COPD: Chronic obstructive pulmonary disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.

Change in the difference between the future liver remnant volume and the functional future liver remnant volume after portal vein embolization. In three patients (solid lines), the functional future liver remnant volume became lower than the future liver remnant volume at 2 wk after portal vein embolization. W: Week. Comparison of the background factors between the functional future liver remnant volume superior group and future liver remnant volume superior group Functional future liver remnant volume (FFLRV) superior group included the patients without FFLRV decrease below the future liver remnant volume (FLRV) at 2 wk after PVE. FLRV superior group included the patients with FFLRV decrease below the FLRV at 2 weeks after PVE. SD: Standard deviation; COPD: Chronic obstructive pulmonary disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.

Representative case

A 77-year-old woman was diagnosed with hilar cholangiocarcinoma. Right hepatectomy and caudal lobectomy were planned. PVE was performed because the initial resection ratio was 71.3%. FLRV increased from 414 mL to 796 mL at two weeks after PVE; however, the change in function lagged behind the increase in FLRV for 3 wk (Figure 3A). The decrease in the FLR to spleen CT attenuation ratio at up to 5 wk after PVE indicated fatty changes in the FLR. Biopsy at 4 wk after PVE showed macro- and micro-vesicular steatosis of more than 40% (Figure 3B). FLRV on CT was sufficient to proceed with resection, although we postponed the operation until the FLR to spleen CT attenuation ratio recovered. Pioglitazone was administered for the treatment of nonalcoholic fatty liver disease. The CT attenuation ratio recovered at 7 wk after PVE, and radical liver resection was successfully performed at 13 wk. Intraoperative biopsy showed that the steatosis had improved to approximately 10% (Figure 3C). The patient recovered uneventfully without any symptoms of postoperative liver failure.
Figure 3

Change in the difference between the future liver remnant volume and the functional future liver remnant volume after portal vein embolization and biopsy findings in patient 1. A: Change in future liver remnant volume (FLRV), functional FLRV (FFLRV), and future liver remnant (FLR) to spleen computed tomography (CT) attenuation ratio in patient 1. The FFLRV level remained below that of the FLRV at 2 wk after portal vein embolization (PVE). The decrease in the FLR to spleen CT attenuation ratio represents fatty changes in FLR at 5 wk after PVE; B: Biopsy findings in the FLR at 4 wk after PVE. The macro and micro-vesicular steatosis was more than 40%; C: At 13 wk after PVE, the steatosis had improved to approximately 10%. W: Week.

Change in the difference between the future liver remnant volume and the functional future liver remnant volume after portal vein embolization and biopsy findings in patient 1. A: Change in future liver remnant volume (FLRV), functional FLRV (FFLRV), and future liver remnant (FLR) to spleen computed tomography (CT) attenuation ratio in patient 1. The FFLRV level remained below that of the FLRV at 2 wk after portal vein embolization (PVE). The decrease in the FLR to spleen CT attenuation ratio represents fatty changes in FLR at 5 wk after PVE; B: Biopsy findings in the FLR at 4 wk after PVE. The macro and micro-vesicular steatosis was more than 40%; C: At 13 wk after PVE, the steatosis had improved to approximately 10%. W: Week.

DISCUSSION

In the present study investigating the sequential relationship between the increase in FLRV and the functional changes after preoperative PVE, we found that in almost all cases, the increase in FLRV lagged behind that of the FFLRV. However, several cases of marked lagging of the FFLRV behind the increase in FLRV within the first 2 wk were observed. Embolized lobe atrophy and FLR hypertrophy occur after PVE[12]. A meta-analysis reported the mean relative rate of hypertrophy of FLR to be 43.1%[23]. In this study, the increase in FLRV at 2 wk was 36.8% ± 18.9%, which is roughly in accordance with the previously published mean value. The increase in FFLRV at 2 wk (64.2% ± 33.3%) was greater than that of the FLRV. Beppu et al[14] also reported the marked increase in FLR after PVE using 99mTc-GSA scintigraphy SPECT-CT fusion data. They reported that the percentage increase in FLRV after PVE was greater than that of the non-tumorous remnant liver volume. Moreover, the increased portal flow, heat shock protein (HSP), ATP (adenosine triphosphate) concentrations, and DNA synthesis in the non-embolized liver after PVE may be related to the mechanism of hyper-function of the FLR[24]. Functional transition evidently occurs after PVE because of the hypofunction of the embolized lobe and hyperfunction of the FLR. Moreover, as for the sequential relationship between FLRV increases and FFLRV, 3 patients experienced a marked decrease in FFLRV to levels below the FLRV at 2 wk after PVE. While these patients did not share obvious similarities, rapidly progressive fatty changes in FLR were observed after PVE in 1 patient. Tsai et al[25] reported the first case of acute non-alcoholic fatty change in the liver after PVE, suggesting a relationship between hemodynamic changes after PVE and fatty changes. A time-dependent fatty change in FLR was proven by biopsy in our study. There is a possible hypothesis on the mechanism underlying these fatty changes. Miyake et al[26] reported that HSP70 Levels after right PVE were 2- to 4-fold higher in the non-embolized lobe than in the embolized lobe in 4 of 5 patients[24,26]. The patient who did not experience this marked increase ultimately died of hepatic failure after extended right hepatic lobectomy. Archer et al[27] also showed that the decrease in HSP72 by siHSP72 Leads to lipid accumulation in the primary mouse hepatocytes. Thus, inhibition of HSP70 induction in the FLR after PVE may lead to fatty changes in the FLR and delay functional transition. In contrast, it was demonstrated that liver steatosis quantified with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid -enhanced liver MRI was associated with an impaired growth of FLR after portal vein occlusion in clinical cases[28], and steatotic rats fed with a methionine-choline-deficient diet demonstrated impaired liver generation and less FLR function compared to control rats after portal vein ligation[29]. Increase in FLRV has generally only been used to determine the timing of hepatectomy after PVE; however, the risk of postoperative liver failure remains in some cases due to the functional transition lagging behind the increase in FLRV after PVE. However, in most cases, the increase in FFLRV is larger than that of FLRV after PVE. Therefore, both FLRV and FFLRV must be carefully considered when hepatectomy is performed. Furthermore, besides CT volumetry, evaluation of function with GSA is required. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) enables rapid and extensive hypertrophy of the remnant liver[30]. However, higher morbidity and mortality rates have been reported compared to the conventional methods of volume enhancement[31]. Olthof et al[32] reported that the increase in the function of the FLR was less than that of the volume after stage 1. Calculation of FFLRV using 3D CT and 99mTc-GSA SPECT fusion images may contribute to the improvement of the safety of ALPPS. One of the limitations of this study is that only one of three patients who experienced a marked decrease in FFLRV to levels below the FLRV showed fatty changes in FLR after PVE. There could be multiple causes underlying the lagging of FFLRV behind the increase of FLRV. A large prospective study is needed to elucidate the underlying mechanism of the functional transition delay and fatty changes in FLR. Additionally, the effect of functional transition delay in clinical results, including postoperative liver failure, should be investigated in future studies.

CONCLUSION

Although in most cases, the increase in FLRV lagged behind that of the FFLRV after PVE, the functional transition lagged behind the increase in FLRV in some cases. Evaluation of both volume and function by CT volumetry and 99mTc-GSA is required to determine the optimal timing of hepatectomy after PVE.

ARTICLE HIGHLIGHTS

Research background

Preoperative portal vein embolization (PVE) is a widely used strategy to enable major hepatectomy in patients with insufficient liver remnant. The timing of hepatectomy after PVE has been usually determined from future liver remnant volume (FLRV) based on computed tomography (CT) volumetry.

Research motivation

PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase in FLRV corresponds to the functional transition after PVE remains uncertain.

Research objectives

The present study investigated the sequential relationship between the increase in the FLRV and functional transition after preoperative PVE.

Research methods

Thirty-three patients who underwent major hepatectomy following PVE were enrolled in this retrospective study. Functional FLRV (FFLRV) was defined as the total liver volume × (FLR volume counts / total liver volume counts) on the 3-dimensional 99mTc-galactosyl-human serum albumin (99mTc-GSA) single-photon emission CT CT-fused images. The calculated FFLRV was compared with FLRV.

Research results

FFLRV increased by a significantly larger extent than FLRV at 1 and 2 wk after PVE (P < 0.01); however, in 3 of the 33 patients, FFLRV levels decreased below FLRV at 2 wk. One of the three patients showed rapidly progressive fatty changes in FLR.

Research conclusions

The results indicate that functional transition lagged behind the increase in FLRV after PVE in some cases. The evaluation of both volume and function by CT volumetry and 99mTc-GSA are needed to determine the optimal timing of hepatectomy after PVE for preventing fatal liver failure after major hepatectomy.

Research perspectives

Further research is needed to elucidate the underlying mechanism of the functional transition delay and fatty changes in FLR.
  32 in total

1.  Significance of functional hepatic resection rate calculated using 3D CT/(99m)Tc-galactosyl human serum albumin single-photon emission computed tomography fusion imaging.

Authors:  Yosuke Tsuruga; Toshiya Kamiyama; Hirofumi Kamachi; Shingo Shimada; Kenji Wakayama; Tatsuya Orimo; Tatsuhiko Kakisaka; Hideki Yokoo; Akinobu Taketomi
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

2.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Authors:  Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

3.  The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection.

Authors:  M J Schindl; D N Redhead; K C H Fearon; O J Garden; S J Wigmore
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

4.  Preoperative portal vein embolization for major liver resection: a meta-analysis.

Authors:  Adel Abulkhir; Paolo Limongelli; Andrew J Healey; Osama Damrah; Paul Tait; James Jackson; Nagy Habib; Long R Jiao
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

5.  Liver-fat and liver-function indices derived from Gd-EOB-DTPA-enhanced liver MRI for prediction of future liver remnant growth after portal vein occlusion.

Authors:  Borna K Barth; Michael A Fischer; Patryk Kambakamba; Mickael Lesurtel; Caecilia S Reiner
Journal:  Eur J Radiol       Date:  2016-02-06       Impact factor: 3.528

6.  Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy.

Authors:  John T Mullen; Dario Ribero; Srinevas K Reddy; Matteo Donadon; Daria Zorzi; Shiva Gautam; Eddie K Abdalla; Steven A Curley; Lorenzo Capussotti; Bryan M Clary; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2007-02-15       Impact factor: 6.113

7.  Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.

Authors:  K Kubota; M Makuuchi; K Kusaka; T Kobayashi; K Miki; K Hasegawa; Y Harihara; T Takayama
Journal:  Hepatology       Date:  1997-11       Impact factor: 17.425

8.  Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience.

Authors:  Giorgio Giraudo; Michel Greget; Elie Oussoultzoglou; Edoardo Rosso; Philippe Bachellier; Daniel Jaeck
Journal:  Surgery       Date:  2008-04       Impact factor: 3.982

9.  Heat shock protein 70 induction in hepatocytes after right portal vein embolization.

Authors:  Hidenori Miyake; Masahiko Fujii; Katsuya Sasaki; Tsutomu Ando; Shizuo Ikeyama; Takashi Iwata; Kazuhito Rokutan; Seiki Tashiro
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec

10.  Uneven acute non-alcoholic fatty change of the liver after percutaneous transhepatic portal vein embolization in a patient with hilar cholangiocarcinoma - a case report.

Authors:  Chun-Yi Tsai; Motoi Nojiri; Yukihiro Yokoyama; Tomoki Ebata; Takashi Mizuno; Masato Nagino
Journal:  BMC Gastroenterol       Date:  2017-12-06       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.